APA

Rogers K. A., Mousa L., Zhao Q., Bhat S. A., Byrd J. C., El Boghdadly Z., Guerrero T., Levine L. B., Lucas F., Shindiapina P., Sigmund A. M., Sullivan M., Wiczer T. E., Woyach J. A. & Awan F. T. (20200203). Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. : Leukemia.

Chicago

Rogers Kerry A, Mousa Luay, Zhao Qiuhong, Bhat Seema A, Byrd John C, El Boghdadly Zeinab, Guerrero Tomas, Levine Lauren B, Lucas Fabienne, Shindiapina Polina, Sigmund Audrey M, Sullivan Matthew, Wiczer Tracy E, Woyach Jennifer A and Awan Farrukh T. 20200203. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. : Leukemia.

Harvard

Rogers K. A., Mousa L., Zhao Q., Bhat S. A., Byrd J. C., El Boghdadly Z., Guerrero T., Levine L. B., Lucas F., Shindiapina P., Sigmund A. M., Sullivan M., Wiczer T. E., Woyach J. A. and Awan F. T. (20200203). Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. : Leukemia.

MLA

Rogers Kerry A, Mousa Luay, Zhao Qiuhong, Bhat Seema A, Byrd John C, El Boghdadly Zeinab, Guerrero Tomas, Levine Lauren B, Lucas Fabienne, Shindiapina Polina, Sigmund Audrey M, Sullivan Matthew, Wiczer Tracy E, Woyach Jennifer A and Awan Farrukh T. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. : Leukemia. 20200203.